182 related articles for article (PubMed ID: 33246602)
1. Targeting and imaging of HER2 overexpression tumor with a new peptide-based
Biabani Ardakani J; Akhlaghi M; Nikkholgh B; Hosseinimehr SJ
Bioorg Chem; 2021 Jan; 106():104474. PubMed ID: 33246602
[TBL] [Abstract][Full Text] [Related]
2. Initial preclinical evaluation of 68 Ga-DOTA-(Ser) 3 -LTVSPWY peptide as a PET radiotracer for glioblastoma targeting and imaging.
Ranjbar V; Molavipordanjani S; Biabani Ardakani J; Akhlaghi M; Nikkholgh B; Hosseinimehr SJ
Nucl Med Commun; 2022 Aug; 43(8):945-951. PubMed ID: 35754162
[TBL] [Abstract][Full Text] [Related]
3. An improved
Khodadust F; Ahmadpour S; Aligholikhamseh N; Abedi SM; Hosseinimehr SJ
Eur J Med Chem; 2018 Jan; 144():767-773. PubMed ID: 29291444
[TBL] [Abstract][Full Text] [Related]
4. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
[TBL] [Abstract][Full Text] [Related]
5. A 2-helix small protein labeled with 68Ga for PET imaging of HER2 expression.
Ren G; Zhang R; Liu Z; Webster JM; Miao Z; Gambhir SS; Syud FA; Cheng Z
J Nucl Med; 2009 Sep; 50(9):1492-9. PubMed ID: 19690041
[TBL] [Abstract][Full Text] [Related]
6. The preclinical study of
Molavipordanjani S; Mousavi T; Khorramimoghaddam A; Talebpour Amiri F; Abedi SM; Hosseinimehr SJ
Ann Nucl Med; 2023 Jul; 37(7):400-409. PubMed ID: 37115407
[TBL] [Abstract][Full Text] [Related]
7. Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics.
Kumar P; Tripathi SK; Chen CP; Wickstrom E; Thakur ML
Mol Imaging Biol; 2019 Feb; 21(1):130-139. PubMed ID: 29802552
[TBL] [Abstract][Full Text] [Related]
8. PET imaging of a
Xu Y; Wang L; Pan D; Yu C; Mi B; Huang Q; Sheng J; Yan J; Wang X; Yang R; Yang M
Br J Radiol; 2019 Dec; 92(1104):20190425. PubMed ID: 31593482
[TBL] [Abstract][Full Text] [Related]
9. A Novel Small Cyclic Peptide-Based
Liu H; Hu M; Deng J; Zhao Y; Peng D; Feng Y; Wang L; Chen Y; Qiu L
Mol Pharm; 2022 Jan; 19(1):138-147. PubMed ID: 34910492
[TBL] [Abstract][Full Text] [Related]
10. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules.
Qi S; Hoppmann S; Xu Y; Cheng Z
Mol Imaging Biol; 2019 Oct; 21(5):907-916. PubMed ID: 30617730
[TBL] [Abstract][Full Text] [Related]
11. In vivo targeting of HER2-positive tumor using 2-helix affibody molecules.
Ren G; Webster JM; Liu Z; Zhang R; Miao Z; Liu H; Gambhir SS; Syud FA; Cheng Z
Amino Acids; 2012 Jul; 43(1):405-13. PubMed ID: 21984380
[TBL] [Abstract][Full Text] [Related]
12. 68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET.
Kramer-Marek G; Shenoy N; Seidel J; Griffiths GL; Choyke P; Capala J
Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):1967-76. PubMed ID: 21748382
[TBL] [Abstract][Full Text] [Related]
13. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A
Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
[TBL] [Abstract][Full Text] [Related]
14. Comparative studies of three 68Ga-labeled [Des-Arg10]kallidin derivatives for imaging bradykinin B1 receptor expression with PET.
Lin KS; Amouroux G; Pan J; Zhang Z; Jenni S; Lau J; Liu Z; Hundal-Jabal N; Colpo N; Bénard F
J Nucl Med; 2015 Apr; 56(4):622-7. PubMed ID: 25745086
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Preclinical Evaluation of a
Li H; Yuan L; Long Y; Fang H; Li M; Liu Q; Xia X; Qin C; Zhang Y; Lan X; Gai Y
Mol Pharm; 2020 Aug; 17(8):3000-3008. PubMed ID: 32544337
[TBL] [Abstract][Full Text] [Related]
16. A novel 18F-labeled two-helix scaffold protein for PET imaging of HER2-positive tumor.
Miao Z; Ren G; Jiang L; Liu H; Webster JM; Zhang R; Namavari M; Gambhir SS; Syud F; Cheng Z
Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):1977-84. PubMed ID: 21761266
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Neuropeptide Y1 Receptor for Cancer Imaging by Positron Emission Tomography Using Novel Truncated Peptides.
Zhang C; Pan J; Lin KS; Dude I; Lau J; Zeisler J; Merkens H; Jenni S; Guérin B; Bénard F
Mol Pharm; 2016 Nov; 13(11):3657-3664. PubMed ID: 27669056
[TBL] [Abstract][Full Text] [Related]
18. First-in-human validation of enzymolysis clearance strategy for decreasing renal radioactivity using modified [
Zhang M; Kang F; Xing T; Wang J; Ma T; Li G; Quan Z; Yang W; Chen X; Wang J
Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1713-1724. PubMed ID: 38216779
[TBL] [Abstract][Full Text] [Related]
19. Primary Preclinical and Clinical Evaluation of
Li F; Zhang Z; Cai J; Chen X; Zhou Y; Ma X; Dong Q; Li F; Xi L
Clin Cancer Res; 2020 Mar; 26(6):1318-1326. PubMed ID: 31843751
[TBL] [Abstract][Full Text] [Related]
20. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
